MedTrace Logo

Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)

NCT01869881 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2021-04-23

No results posted yet for this study

Summary

Phase 4 Study to evaluate the safety and effect on decreasing subjects' albuminuria who have Type 2 Diabetes by using sarpogrelate and placebo.

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

Anplag(Sarpogrelate)

Sarpogrelate 100mg 2 tablets, bid, 400mg/day

DRUG

Placebo

Placebo 100mg 2 tablets, bid, 400mg/day

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • D.S Choi, MD, PhD · Korea University Hospital, Anam

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-01
Primary Completion
2014-11-17
Completion
2015-01-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01869881 on ClinicalTrials.gov